<?xml version="1.0" encoding="UTF-8"?>
<p>Other candidates, such as Naproxen, a non-steroidal anti-inflammatory drug, was shown to target NP protein at residues F209 and Y148, thus antagonizes the CRM1-mediated nuclear export of NP. It is suggested to have a broad-spectrum anti-influenza activity [
 <xref rid="B232-viruses-12-00376" ref-type="bibr">232</xref>]. Verdinexor (KPT-335), a novel orally bioavailable drug, blocks CRM1-mediated nuclear export of NP and repress NF-ÎºB activation, thus reducing cytokine production and eliminating virus-associated immunopathology [
 <xref rid="B233-viruses-12-00376" ref-type="bibr">233</xref>]. For further reading on candidate anti-IV therapeutics, a review summarized by Davidson is recommended here [
 <xref rid="B234-viruses-12-00376" ref-type="bibr">234</xref>].
</p>
